Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Down 85.5% in January

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 2,000 shares, a drop of 85.5% from the January 15th total of 13,800 shares. Based on an average daily trading volume, of 57,000 shares, the days-to-cover ratio is presently 0.0 days.

Appili Therapeutics Stock Down 14.4 %

Shares of OTCMKTS APLIF opened at $0.02 on Friday. The company has a market capitalization of $2.38 million, a PE ratio of -0.98 and a beta of -0.53. The stock’s 50 day moving average price is $0.02 and its 200-day moving average price is $0.03. Appili Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.05.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.